Summit Therapeutics Inc. Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019
Summit Therapeutics Inc. (SMMT) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 of 0 GBP/shares for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 · last filed 2020-06-02
- Summit Therapeutics Inc. weighted average exercise price of share options granted in share-based payment arrangement2019 for the quarter ending 2020-03-31 was 0.00 GBP/shares, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. weighted average exercise price of share options granted in share-based payment arrangement2019 for the quarter ending 2019-03-31 was 0.28 GBP/shares.
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 3 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 11 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month |
|---|---|---|---|
| 2020-03-31 | 0.00 GBP/shares 6-K · filed 2020-06-02 | ||
| 2019-12-31 | 0.27 GBP/shares 20-F · filed 2020-04-30 | ||
| 2019-03-31 | 0.28 GBP/shares 6-K · filed 2020-06-02 | ||
| 2019-01-31 | 0.76 GBP/shares 20-F · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |